Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis.
Eicosapentaenoic acid (EPA) is one of the major components of fish oil, which was reported to have antiatherogenic, anti-inflammatory and immune suppressive effects. In the present study, highly purified EPA was administered to patients with lupus nephritis and the effects of EPA on urinary 8-isoprostane, a reliable marker of oxidative stress, were investigated in these patients. Six outpatients (1 man and 5 women), with lupus nephritis diagnosed by renal biopsy, were entered in the study. We administered 1800 mg EPA ethyl-ester (purity > 95%) daily and examined the urinary 8-isoprostane levels and plasma fatty acid composition before and 3 months after EPA treatment. The urinary 8-isoprostane levels were significantly decreased after the treatment compared with those before the treatment (from 530 +/- 113 pg/mg x Cr to 235 +/- 49 pg/mg x Cr, p = 0.02). The EPA levels in the plasma phospholipid (PL) fraction were significantly increased after the treatment (from 3.30 +/- 0.64 mol% to 8.01 +/- 0.47 mol%, p < 0.001). Arachidonic acid (AA) levels in the plasma PL fraction were significantly decreased after the treatment (from 9.47 +/- 0.28 mol% to 7.33 +/- 0.43 mol%, p < 0.001). The ratios of EPA to AA were significantly increased after the treatment (from 0.35 +/- 0.07 to 1.14 +/- 0.16, p < 0.001). Thus, this preliminary study indicated that EPA might exert beneficial effects on lupus nephritis by decreasing the oxidative stress.
Nakamura
Norio
N
The Second Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan. nnakamur-tym@umin.ac.jp
Kumasaka
Ryuichiro
R
Osawa
Hiroshi
H
Yamabe
Hideaki
H
Shirato
Ken-Ichi
K
Fujita
Takeshi
T
Murakami
Rei-Ichi
R
Shimada
Michiko
M
Nakamura
Masayuki
M
Okumura
Ken
K
Hamazaki
Kei
K
Hamazaki
Tomohito
T
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001706:Biopsy; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D005227:Fatty Acids / Q000097:blood* / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008181:Lupus Nephritis / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D005227:Fatty Acids; D010975:Platelet Aggregation Inhibitors; C075750:8-epi-prostaglandin F2alpha; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid; D015237:Dinoprost